Therapie der akuten schweren Colitis ulcerosa im Krankenhaus – Ein Update
暂无分享,去创建一个
[1] S. Vermeire,et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. , 2012, Journal of Crohn's & colitis.
[2] J. Gisbert,et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial , 2012, The Lancet.
[3] A. Griffiths,et al. Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements , 2012, The American Journal of Gastroenterology.
[4] D. Aust,et al. [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. , 2011, Zeitschrift fur Gastroenterologie.
[5] O. Dewit,et al. Successive Treatment With Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis , 2011, The American Journal of Gastroenterology.
[6] A. Hart,et al. Review article: the optimal medical management of acute severe ulcerative colitis , 2010, Alimentary pharmacology & therapeutics.
[7] B. Warren,et al. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications , 2010, The British journal of surgery.
[8] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[9] H. Tilg,et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.
[10] A. Kornbluth,et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] F. Remzi,et al. Infliximab in Ulcerative Colitis is Associated with an Increased Risk of Postoperative Complications After Restorative Proctocolectomy , 2008, Diseases of the colon and rectum.
[12] G. Kaplan,et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. , 2008, Gastroenterology.
[13] Kimberly A. Reske,et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[14] G. Lichtenstein. Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled StudyJärnerot G, Hertervig E, Friis-Liby I, et al (Örebro Univ Hosp, Sweden; Lund Univ Hosp, Sweden; Sahlgrenska Univ Hosp, Gothenburg, Sweden; et al) Gastroenterology 128:1805–1811, 2005 , 2006 .
[15] Å. Danielsson,et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.
[16] S. Travis. Predicting outcome in severe ulcerative colitis. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[17] D. Hommes,et al. The Pathogenicity of Cytomegalovirus in Inflammatory Bowel Disease: A Systematic Review and Evidence-based Recommendations for Future Research , 2004, Inflammatory bowel diseases.
[18] S. Hanauer,et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. , 1994, The New England journal of medicine.